DadFinStart your free week
DadFin › Stocks › Healthcare › ZYBT

Zhengye Biotechnology Holding Limi (ZYBT) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · China

$1.73 ▲ +50.43% today

54.1
Dad Score, out of 100
middling

Zhengye Biotechnology Holding Limi (ZYBT) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in China. On DadFin's weekly run it scores 54.1 out of 100 on the Dad Score, a middling reading that places the business ahead of 54% of the 5,773 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #386 of 968. Its strongest axes are price action and macro; its weakest are quality and growth.

Scores from the run of Oct 11, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Weak
Growth
Weak
Price action
Strong
Risk
Weak
Conviction
Weak
Liquidity
Average
Macro
Strong

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)—
Dividend yield0.00%
Return on capital-17.5%
Operating margin-77.0%
Revenue growth (YoY)-37.6%
FCF yield0.1%
Net debt / EBITDA3.00×
Piotroski F-Score3 / 9
52-week change-39.5%
Market cap$82M
Next earnings—

What subscribers see on ZYBT

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi50.0middling$59.8B
TEVATeva Pharmaceutical Industries Lim96.8strong$47.9B
HLNHaleon plc69.5middling$41.0B
ZTSZoetis Inc.94.4strong$30.9B
UTHRUnited Therapeutics Corporation99.1strong$23.6B
VTRSViatris Inc.84.5good$20.3B
NBIXNeurocrine Biosciences, Inc.98.7strong$14.5B
ELANElanco Animal Health Incorporated96.2strong$11.5B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 11, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.